QPPVEU RegulationGVPMarketing Authorisation

What is a QPPV and does your biotech need one?

March 2026·8 min read·Nimble PV

Few roles in the pharmaceutical industry generate more confusion among small company leadership teams than the Qualified Person for Pharmacovigilance. Founders hear "QPPV" and think of a full-time employee, a very expensive one, required before they can do anything in Europe. That's not quite right — but the truth is nuanced enough that getting it wrong has real regulatory consequences.

Let's be precise. The QPPV is a specific legal requirement under EU pharmaceutical legislation. If your company holds a marketing authorisation in the EU/EEA — whether granted centrally by the EMA or nationally by an EU member state — you are required to have a designated QPPV. If you don't hold an EU marketing authorisation, the QPPV requirement does not apply to you yet.

What the law actually says

The requirement is set out in Article 104(3)(b) of Directive 2001/83/EC, as amended by Directive 2010/84/EU (the Pharmacovigilance Directive). It requires that every Marketing Authorisation Holder (MAH) holding an EU/EEA marketing authorisation:

Appoint a QPPV who resides and operates in the EU/EEA
Register the QPPV's name and contact details with the EMA via EudraVigilance
Ensure the QPPV is permanently and continuously available
Describe the QPPV's role in the Pharmacovigilance System Master File (PSMF)

GVP Module I expands on these obligations significantly, specifying the QPPV's responsibilities in considerable detail. The QPPV is not just a figurehead — they bear genuine personal and legal accountability for the MAH's pharmacovigilance system.

What the QPPV actually does

The QPPV's responsibilities under GVP Module I include:

Oversight of the pharmacovigilance system

The QPPV is responsible for establishing and maintaining the MAH's pharmacovigilance system — the processes, infrastructure, and procedures that govern how adverse events are collected, assessed, and reported. They must be able to demonstrate, on inspection, that the system is functioning correctly and is appropriately documented in the PSMF.

Single point of contact with regulatory authorities

In practice, the QPPV is the person the EMA and national competent authorities (NCAs) call when there is a safety issue. If the EMA requests an urgent safety restriction on one of your products, the QPPV is expected to be reachable and to respond. This "continuously available" requirement is taken seriously by inspectors — it is a common inspection finding when the QPPV is shown to have been on extended leave without an appropriate backup arrangement.

ICSR and aggregate report oversight

The QPPV does not need to personally review every adverse event report — for large MAHs with thousands of cases per year, that would be impossible. But they must have a functioning system under which qualified personnel process ICSRs, and they must personally oversee or sign off on periodic safety reports (PSURs/PBRERs), Risk Management Plans, and significant safety label changes.

Signal detection and evaluation

The QPPV is responsible for ensuring that signal detection activities are conducted across all marketed products, that signals are evaluated in accordance with GVP Module IX timelines, and that any confirmed signals are escalated to the EMA or relevant NCA appropriately.

PSMF maintenance

The Pharmacovigilance System Master File is the central document describing the MAH's PV system. The QPPV is personally responsible for its accuracy and currency. GVP Module II specifies detailed PSMF content requirements — the QPPV's CV, organisational charts, system descriptions, quality system procedures, and audit logs. An out-of-date or incomplete PSMF is one of the most common and damaging GVP inspection findings.

What qualifications does a QPPV need?

The legislation does not specify a precise qualification — it requires that the QPPV has "appropriate pharmacovigilance expertise". In practice, NCAs and the EMA expect a QPPV to have:

A medical degree, pharmacy degree, or life sciences PhD, plus relevant postgraduate training in drug safety
Several years of direct pharmacovigilance experience, including ICSR management, aggregate reporting, and signal detection
Detailed working knowledge of EU GVP modules and ICH guidelines
Direct experience of EMA or NCA regulatory interactions

This profile describes a relatively senior person. Genuinely qualified QPPVs who are also EU-resident are not abundant. For smaller companies, this creates a real staffing challenge — you cannot simply promote a junior pharmacovigilance analyst to QPPV and expect regulators to be satisfied.

What inspectors look for: The EMA and NCAs assess whether the QPPV has the authority, capability, and resource to actually fulfil the role. A QPPV who is listed in the PSMF but who has no meaningful oversight of the PV system — a figurehead arrangement — is a significant inspection finding. The QPPV must be able to demonstrate, in person, that they understand the MAH's safety database, ICSR process, signal detection activities, and the content of any current safety commitments.

Does your biotech need a QPPV right now?

The question has a clear answer based on your regulatory stage:

You are in Phase 1–3 clinical development only (IND/CTA, no EU MA)

No QPPV required. You need a named safety contact (often called the sponsor's medical officer or safety physician) and appropriate clinical trial safety SOPs, but the QPPV requirement is specific to MAH status. You do not need to appoint a QPPV until you receive your first EU marketing authorisation.

You have submitted or received an EU marketing authorisation

A QPPV must be appointed and registered with the EMA before (or immediately upon) grant of the authorisation. The MAH's application should include the QPPV's details. NCAs will not be satisfied by a "QPPV to be appointed" placeholder — this needs to be a real, named, EU-resident person.

You are preparing a regulatory submission and expect EU approval within 12–18 months

This is the right time to start planning for your QPPV. Recruiting or contracting a QPPV takes time — especially because the pool of genuinely qualified, EU-resident candidates is limited. Identifying your QPPV arrangement and building your PSMF infrastructure 12–18 months before MAA approval is strongly advisable.

Fractional and contracted QPPV arrangements

The EU legislation does not require your QPPV to be a full-time employee. Many small pharma and biotech companies — particularly those with only one or two EU authorisations — use a contracted or fractional QPPV arrangement through a CRO or specialist consultancy.

These arrangements work well if:

The contracted QPPV has genuine authority and access to your safety data and systems
Your internal team has appropriate pharmacovigilance operations support so the QPPV is not operationally overwhelmed
The arrangement is clearly documented in the PSMF, including the QPPV's access rights, oversight responsibilities, and backup arrangements
The QPPV is EU-resident — a non-EU QPPV does not satisfy the legislative requirement

What doesn't work is appointing a contracted QPPV and then not giving them genuine oversight. The QPPV must actually oversee the system, not just lend their name to your regulatory filings.

What does a QPPV cost?

A full-time, employed EU QPPV at a small pharma company typically commands a base salary of £120,000–£180,000 per year in Western Europe, plus benefits and overhead. For a single-product startup, that is a significant fixed cost.

Contracted or fractional QPPV arrangements from a specialist provider typically run at £5,000–£25,000 per year for a small product portfolio with limited PV complexity, though this varies substantially based on portfolio size, safety signal volume, and the level of regulatory interaction required. A startup with a single approved product and a clean safety profile is at the lower end; a company managing multiple authorisations, ongoing aggregate reports, and active safety signals will be at the higher end.

Nimble PV provides fractional QPPV services for small pharma and biotech companies holding EU marketing authorisations. Our QPPVs are EU-resident, GVP-qualified, and have direct EMA inspection experience. If you're preparing for an EU approval or currently without a QPPV, talk to us →

The QPPV is a strategic asset, not a compliance checkbox

The most valuable QPPVs we've seen in practice are not the ones who sign documents and stay out of the way. They're the ones who understand the product, know the regulators, and have built the relationships and infrastructure that mean a safety signal gets handled cleanly rather than becoming a crisis.

For a small company, appointing the right QPPV — whether fractional or full-time — is one of the highest-leverage pharmacovigilance decisions you will make. Get it right early, and it's a foundation. Get it wrong, and it becomes the first line of an inspection finding.